WVE · CIK 0001631574 · operating
Wave Life Sciences is a clinical-stage biotechnology company developing RNA-based medicines through its PRISM platform, which combines multiple RNA modalities, chemistry approaches, and genetic insights to address rare and common diseases. The company's pipeline includes WVE-006, an RNA editing oligonucleotide for alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA for obesity; WVE-N531, an exon skipping oligonucleotide for Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for Huntington's disease. The company has established collaboration agreements with GlaxoSmithKline and Takeda Pharmaceutical Company Limited for research and development of oligonucleotide therapeutics across multiple therapeutic areas, and partners with Asuragen for companion diagnostic development.
Based in Singapore with 287 full-time employees, Wave Life Sciences was incorporated in 2012 and is listed on Nasdaq. The company operates as a pre-commercial entity focused on advancing its RNA medicine candidates through clinical development stages, with revenue generation dependent on the progression and eventual commercialization of its pipeline programs and milestone payments from strategic partnerships.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-1.21 | $-1.21 | -72.9% | |
| 2024 | $-0.70 | $-0.70 | -29.6% | |
| 2023 | $-0.54 | $-0.54 | +73.7% | |
| 2022 | $-2.05 | $-2.05 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-26 | 0001193125-26-073472 | SEC ↗ |
| 2024-12-31 | 2025-03-04 | 0000950170-25-031322 | SEC ↗ |
| 2023-12-31 | 2024-03-06 | 0000950170-24-026876 | SEC ↗ |
| 2022-12-31 | 2023-03-23 | 0000950170-23-009319 | SEC ↗ |
| 2021-12-31 | 2022-03-03 | 0001564590-22-008414 | SEC ↗ |
| 2020-12-31 | 2021-03-04 | 0001564590-21-010718 | SEC ↗ |
| 2019-12-31 | 2020-03-02 | 0001564590-20-007972 | SEC ↗ |
| 2018-12-31 | 2019-03-01 | 0001564590-19-005671 | SEC ↗ |
| 2017-12-31 | 2018-03-12 | 0001564590-18-005308 | SEC ↗ |
| 2016-12-31 | 2017-03-16 | 0001564590-17-004649 | SEC ↗ |
| 2015-12-31 | 2016-03-30 | 0001193125-16-523890 | SEC ↗ |